{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sandor A"],"funding":["\"Iuliu Hatieganu\" University of Medicine and Pharmacy, Cluj-Napoca, Romania","Iuliu Hatieganu\" University of Medicine and Pharmacy, Cluj-Napoca, Romania","“Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania"],"pagination":["534"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10141396"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(4)"],"pubmed_abstract":["The epidermal growth factor receptor (EGFR) plays a critical role in the tumorigenesis of various forms of cancer. Targeting the mutant forms of EGFR has been identified as an attractive therapeutic approach and led to the approval of three generations of inhibitors. The quinazoline core has emerged as a favorable scaffold for the development of novel EGFR inhibitors due to increased affinity for the active site of EGFR kinase. Currently, there are five first-generation (gefitinib, erlotinib, lapatinib, vandetanib, and icotinib) and two second-generation (afatinib and dacomitinib) quinazoline-based EGFR inhibitors approved for the treatment of various types of cancers. The aim of this review is to outline the structural modulations favorable for the inhibitory activity toward both common m"],"journal":["Pharmaceuticals (Basel, Switzerland)"],"pubmed_title":["Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present)."],"pmcid":["PMC10141396"],"funding_grant_id":["PCD 881/45/12.01.2022","PCD 772/36/11.01.2023"],"pubmed_authors":["Sandor A","Oniga I","Eniu D","Ionut I","Oniga O","Marc G"],"additional_accession":[]},"is_claimable":false,"name":"Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present).","description":"The epidermal growth factor receptor (EGFR) plays a critical role in the tumorigenesis of various forms of cancer. Targeting the mutant forms of EGFR has been identified as an attractive therapeutic approach and led to the approval of three generations of inhibitors. The quinazoline core has emerged as a favorable scaffold for the development of novel EGFR inhibitors due to increased affinity for the active site of EGFR kinase. Currently, there are five first-generation (gefitinib, erlotinib, lapatinib, vandetanib, and icotinib) and two second-generation (afatinib and dacomitinib) quinazoline-based EGFR inhibitors approved for the treatment of various types of cancers. The aim of this review is to outline the structural modulations favorable for the inhibitory activity toward both common m","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2026-04-08T13:33:41.127Z","creation":"2025-02-19T04:46:14.93Z"},"accession":"S-EPMC10141396","cross_references":{"pubmed":["37111291"],"doi":["10.3390/ph16040534"]}}